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Context: Increasedplasma levels of glucose-dependent insulinotropic polypeptide (GIP), calcitonin
CT gene-related peptide (CGRP)-I, and procalcitonin (Pro-CT) are associated with obesity. Adipo-
cytes express functional GIP receptors and the CT peptides Pro-CT and CGRP-I. However, a link
between GIP and CT peptides has not been studied yet.
Objective: The objective of the study was the assessment of the GIP effect on the expression and
secretion of CGRP-I and Pro-CT in human adipocytes, CGRP-I and CT gene expression in adipose
tissue (AT) fromobesevs. lean subjects, andplasma levelsofCGRP-I andPro-CTafterahigh-fatmeal
in obese patients.
Design and Participants: Human preadipocyte-derived adipocytes, differentiated in vitro, were
treatedwithGIP.mRNAexpressionandproteinsecretionofCGRP-IandPro-CTweremeasured.Human
CGRP-I and CTmRNA expression in AT and CGRP-I and Pro-CT plasma concentrations were assessed.
Results: Treatment with 1 nM GIP induced CGRP-I mRNA expression 6.9  1.0-fold (P  0.001 vs.
control) after 2 h and CT gene expression 14.0  1.7-fold (P  0.001 vs. control) after 6 h. GIP
stimulated CGRP-I secretion 1.7  0.2-fold (P  0.05 vs. control) after 1 h. In AT samples of obese
subjects, CGRP-I mRNA expression was higher in sc AT (P  0.05 vs. lean subjects), whereas CT
expressionwashigher in visceralAT (P0.05 vs. lean subjects). CGRP-I plasma levels increasedafter
a high-fat meal in obese patients.
Conclusion:GIP inducesCGRP-IandCTexpression inhumanadipocytes. Therefore, elevatedPro-CT
and CGRP-I levels in obesity might result from GIP-induced Pro-CT and CGRP-I release in AT and
might be triggered by a high-fat diet. How these findings relate to themetabolic complications of
obesity warrants further investigations. (J Clin Endocrinol Metab 96: E297–E303, 2011)
Glucose-dependent insulinotropic polypeptide (GIP) isan incretin hormone released from enteroendocrine
Kcells in response tooral nutrient ingestion,with fat being
the main trigger (1). Obesity is associated with elevated
fasting and postprandial GIP levels (2, 3). Ablation of GIP
signaling protects against diet-induced obesity and insulin
resistance in rodents (4–7). In addition to its role as an
insulinotropic peptide (8), GIP acts on multiple target or-
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gans via G protein-coupled receptors (9). Functional GIP
receptors (GIP-Rs) are expressed by human adipocytes,
using cAMP as second messenger (10). In rodent adipo-
cytes, GIP directly influences fat metabolism and lipid ac-
cumulation (11). Therefore, GIP links diet-induced obe-
sity and related metabolic dysfunctions.
Calcitonin (CT) peptides like CT gene-related peptide
(CGRP)-I andprocalcitonin (Pro-CT) arederived fromthe
CALC-I gene by alternative splicing (12). They are ex-
pressed and released from adipose tissue (AT) during sep-
sis and systemic inflammation (13–15) and from adipo-
cytes treated with inflammatory cytokines in vitro (14–
16). Pro-CT is a widely used surrogatemarker in bacterial
infection and sepsis (17). In addition, Pro-CT is a marker
of the chronic inflammatory activity of AT inwomenwith
the polycystic ovary syndrome (18), correlating with total
fatmass, body fat distribution, and insulin resistance (18).
Furthermore, a recent study reported an association of
circulating Pro-CT concentrations with obesity and insu-
lin resistance (19). Increased plasma levels of CGRP have
been detected in obese vs. lean women in the fasting state
(20) and after an oral high-fat load in lean subjects (20). In
addition, CGRP induces insulin resistance in muscle and
liver in vitro and in vivo (21–23), whereas other studies
reportedadirect effectofCGRPonpancreatic-cells lead-
ing to impaired insulin secretion in humans (24), rats (25),
and mice (26).
Because plasma levels of GIP (1) as well as Pro-CT (19)
and CGRP (20) are elevated in the state of obesity and
insulin resistance, we examined a potential link between
GIP and theCALC-I gene derived peptides. We tested the
hypothesis that GIP stimulates CGRP-I and Pro-CT ex-
pression and secretion in human adipocytes.We also eval-
uated CGRP-I and CT mRNA expression patterns in sc
and visceral AT from obese vs. lean subjects and plasma
levels of CGRP-I and Pro-CT after high-fat meal ingestion
in morbidly obese patients.
Materials and Methods
Human AT sampling, adipocyte culture, and
treatment
Human AT samples were obtained from patients undergoing
elective surgery. All patients were operated for nonmalignant
and noninflammatory diseases. The study was approved by the
local ethical committee, and written informed consent was ob-
tained from every patient. For AT mRNA expression studies,
paired samples of sc and visceral AT were obtained from seven
lean patients [threemales and four females, aged 64.0 15.0 yr;
body mass index (BMI) 22.7  2.0 kg/m2; none of seven with
diabetes mellitus type 2; C-reactive protein 11.8 8.3 mg/liter]
and 13 morbidly obese patients (four males and nine females,
aged 41.8  11.4 yr; BMI 43.2  3.3 kg/m2; three of 13 with
diabetesmellitus type 2; C-reactive protein, 11.0 6.1mg/liter),
respectively. Adipocyte-containing tissue was macroscopically
dissected from nonadipose tissue and blood vessels and minced
into very small pieces (5 g). TRI reagent was added; the tissue
was vortexed and needled with a syringe (1.2  40 mm). After
centrifugation at 14,000 rpm for 10min at 4 C, the fat layer was
removed and the fluid phase was transferred into a fresh tube.
mRNA was isolated as described below.
For in vitro cell culture experiments, the stromal vascular cell
fraction was isolated from sc AT samples, cultured, and differ-
entiated for 14 d as previously described (27, 28). After 14 d of
differentiation, cells were washed twice with warm PBS and in-
cubated in 5 mM glucose DMEM/F12 containing 3% fetal calf
serum, supplemented with 50 g/ml gentamycin, 15 nM HEPES
(all from Invitrogen, Basel, Switzerland), 100nML-ascorbic acid,
8 g/ml biotin, and 15 mM d-pantothenat (all from Sigma-Al-
drich, Buchs, Switzerland) for 48 h. Thereafter the medium was
renewed and adipocytes were exposed to human recombinant
GIP (1–42) (BachemAG, Bubendorf, Switzerland) for indicated
time points (1–24 h) and concentrations (10 pM to 100 nM).
Adipocytes were treated with human GIP-R antagonist GIP (6–
30) (100 nM to 1 M, preincubation 15 min; Bachem), the ad-
enylyl cyclase activator forskolin (10M, 1 h;Merck Chemicals,
Nottingham,UK), theproteinkinaseA (PKA) inhibitorH-89 (20
M, preincubation 1 h; Merck, Dietikon, Switzerland), and the
ionophor ionomycin (1 M, preincubation 1 h; Sigma-Aldrich).
Cells from passages 2 through 7 were used in all experiments.
RNA isolation and quantitative analysis of mRNA
expression of preadipocyte-derived adipocytes and
human AT samples
RNAwas isolated, 1g total RNAwas subjected to RT-PCR
and cDNAwas subjected to quantitative real-time PCR analysis
as previously described (16). Optimal sets of primers yielding
short PCR products suitable for SYBR-Green detection were
designed using the Probe Finder (Roche Applied Bioscience;
http://qpcr2.probefinder.com). The oligonucleotide primers
used were: 5-GTC ATT CCC TGG GTG ATC GT-3, 5-CCA
CCA AAT GGC CTT GAC TT-3 (GIP-R); 5-CCC CCT CAG
CAG CGA GTG A-3, 5-GCA CCG CCA GGA CAT TGT
TG-3 [glucose transporter (GLUT)-4]; 5-TGCCCATCCAAA
AAGTCCA-3, 5-GAAGTCCAAACCGGTGACTTTCT-3
(leptin); 5-CCC AGA AGA GAG CCT GTG ACA-3, 5-CTT
CAC CAC ACC CCC TGA TC-3 (CGRP-I); 5-GTG CAG
ATG AAG GCC AGT GA-3, 5-TCA GAT TAC CAC ACC
GCT TAG ATC-3 (CT). Each cDNA sample tested for quanti-
tative gene expression was also subjected to hypoxanthine-gua-
nine phosphoribosyltransferase (HPRT)-mRNA analysis. Re-
sults are expressed as ratio of the respective gene of interest and
HPRT-mRNA threshold values. Primers for HPRT were
5-TCAGGCAGTATAATCCAAAGATGGT-3 and5-AGT
CTG GCT TAT ATC CAA CAC TTC-3. The conditions were
set as suggested by the manufacturer.
cAMP measurement
Intracellular cAMP content was determined using the cAMP
Glo assay kit (Promega, Du¨bendorf, Switzerland) with the fol-
lowing modifications to the conditions set by the manufacturer:
cells were starved in serum freeDMEM/F12medium24 h before
treatment. After an incubation period, the supernatant was re-
moved and the cells were harvested in cAMP-lysis buffer, pro-
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vided by the manufacturer and scraped, and the lysate was sub-
jected to a 96-well plate. A standard curve was performed with
cAMP control and cAMP-lysis buffer both provided by the
manufacturer.
Protein measurement in supernatants of
preadipocyte-derived adipocytes
After treatment the supernatants were collected, centrifuged,
and immediately stored at70C. Supernatants were either con-
centrated in vacuo at room temperature for 4 h (GIP treatment
alone) or concentrated for 6 h (experiments with GIP and iono-
mycin). The CGRP-I and Pro-CT protein in cell supernatant was
determined as previously described (16, 28).
Protein measurement in human plasma
EDTA plasma samples from a recently performed study (29)
were kindly donated by the study investigators. Briefly, fasting
EDTA plasma samples from 24 morbidly obese patients (four
males and 20 females, aged 40.47  10.3 yr; BMI 46.12  6.5
kg/m2)wereobtainedafter anovernight fast of at least 10h.After
the fasting period, patients received a high-fat liquid test meal.
We chose the time point of 180 min after meal ingestion for
postprandial proteinmeasurement. CGRP-I and Pro-CT protein
were measured as described previously (16, 28).
Statistical analysis
Datawere analyzed in triplicate usingGraphPadPrism (Prism
4.0 forWindows, SanDiego, CA) and expressed asmeans SEM
unless indicated otherwise. For in vitro data, statistical signifi-
cancewasdeterminedbyANOVAfollowedbyBonferroni’spost
hoc test for multiple comparison analysis or by theMann-Whit-
neyU test when only two groups were analyzed. For analysis of
mRNA expression in human AT, we used theMann-WhitneyU
test. Correlation analyses were performed by using Spearman
rank correlation. For analysis of CGRP-I and Pro-CT protein
concentrations in human plasma samples, we used theWilcoxon
signed rank test.
Results
Expression of functional GIP-R by differentiated
human preadipocyte-derived adipocytes
GIP-R mRNA expression was induced 6846  1255-
fold at d 7 (P0.01 vs.preadipocytes) and 8196962.8-
fold at d 14 (P  0.01 vs. preadipocytes) during the dif-
ferentiation process (Fig. 1A). This was paralleled by the
induction of other adipocyte differentiation markers like
GLUT-4 and leptin (Fig. 1A). To further assess the func-
tionality of the GIP-R in our human adipocytes, we mea-
sured GIP-induced cellular cAMP accumulation. Treat-
ment of differentiated adipocytes with 1 and 100 nM GIP
for 1 h in serum-free conditions produced a 7.1 1.0-fold
(P 0.01 vs. control) and an 8.2 1.4-fold (P 0.001 vs.
control) increase in cAMP accumulation, respectively
(Fig. 1B). Treatment for 1 h with 10 M forskolin served
as a positive control and revealed a 9.8  0.8-fold (P 
0.001 vs. basal) induction of cAMP content (Fig. 1B). Pre-
incubation with 1 M of the GIP-R inhibitor GIP (6–30)
reduced cAMP induction by GIP (1 and 100 nM) without
reaching significance (Fig. 1B).
GIP induced CALC-I gene expression in a dose- and
time-dependent manner
Treatment of human preadipocyte-derived adipocytes
with increasing concentrationsofGIP from1pMto100nM
for 1 h revealed a significant up-regulation of theCALC-I
FIG. 1. Functional GIP-Rs are expressed by differentiated human
preadipocyte-derived adipocytes. A, mRNA expression level of GIP-R,
GLUT-4, and leptin in human preadipocyte-derived adipocytes were
assessed by real-time PCR at d 0 (undifferentiated preadipocytes), d 7
and d 14 of differentiation. mRNA levels are normalized to HPRT
expression levels. Results are expressed in arbitrary units with the
preadipocyte values taken as 1 and are the means  SEM of two
independent experiments of two different donors each carried out in
triplicate. **, P  0.01 vs. preadipocyte expression level of the
respective gene. B, Differentiated adipocytes were serum starved for
2 h and then treated for 1 h with GIP (1 nM, 100 nM) in the presence
or absence of the GIP-R antagonist GIP (6–30) (1 M, preincubation 15
min). Forskolin (10 M) was added for 1 h and served as a positive
control. Cellular cAMP content was determined using a luminescence
assay. Results are expressed in arbitrary units with the control value
taken as 1 and are the means  SEM of three independent experiments
all carried out in triplicate. **, P  0.01; ***, P  0.001 vs. control.
n.s., Not significant vs. GIP 1 nM or GIP 100 nM.
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gene products at 10 and 100 nM. CGRP-ImRNA expres-
sionwas induced 16.7 2.11-fold (P 0.001 vs. control)
at 10 nM GIP and 25.6 4.7-fold (P 0.001 vs. control)
at 100 nM GIP (Fig. 2A).CTmRNA expression was max-
imally induced8.01.5-fold (P0.001 vs. control) at 10
nM GIP and 7.9 2.4-fold (P 0.001 vs. control) at 100
nM GIP (Fig. 2A). CGRP-II was induced in a similar pat-
tern to CGRP-I, albeit to a much lower extent (data not
shown). No significant change in mRNA expression lev-
els was observed for other members of the CALC gene
family, such as adrenomedullin or amylin (data not
shown). Corresponding with barely detectable GIP-R ex-
pression in undifferentiated adipocytes,
GIP treatment of preadipocytes did not
result inachange inCALC-Igeneexpres-
sion levels (data not shown).
To assess the CGRP-I and CT
mRNA expression pattern over time,
differentiated adipocytes were treated
with1nMGIP for24h.CGRP-ImRNA
expression was induced 5.9 0.7-fold
(P  0.001 vs. control) after 1 h, was
maximally increased 6.9  1.0-fold
(P  0.001 vs. control) after 2 h, and
declined slowly thereafter to almost
control level after 24 h (Fig. 2B). Up-
regulation of CT mRNA expression
was delayed compared with CGRP-I
with a 9.2  0.8-fold increase (P 
0.001 vs. control) after 4h anda14.0
1.7-fold increase (P 0.001) after 6 h.
In contrast to CGRP-I, CT mRNA ex-
pressionwas still up-regulated by 7.9
1.5-fold (P  0.01 vs. control) after
24 h. Treatment with 1 nM GIP in-
creased CGRP-I protein content in the
mediumby 1.7 0.2-fold (P 0.05 vs.
control) already after 1 h (Fig. 2C),
whereas Pro-CT secretion was not de-
tectable afterGIP treatment alone (data
not shown).
GIP induced CALC-I gene
expression was inhibited by the
GIP-R inhibitor GIP (6–30)
The stimulatory effect ofGIPwas di-
minished or completely abolished by
pretreatment with GIP (6–30). GIP-in-
duced CGRP-I mRNA expression was
reducedby79%(P0.01vs.GIP1nM,
1 h) at 1 M GIP (6–30) and by 94%
(P 0.001 vs.GIP 1 nM, 1 h) at 10 M
GIP (6–30) (data not shown). GIP-
stimulated CT mRNA expression was reduced by 96%
(P 0.05 vs.GIP 1 nM, 1 h) at 10MGIP (6–30) (data not
shown).
The cAMP/PKA pathway and intracellular calcium
([Ca2]i) are involved in GIP signal transduction
Wenext evaluated the signal transduction,which could
be responsible for the observed effects of GIP. Addition of
forskolin (10 M) for 1 h potentiated the effect of GIP on
CGRP-I and CT mRNA induction (P  0.001 vs. GIP 1
nM, 1 h) and vice versa (data not shown), pointing to the
crucial role of cAMP as second messenger. Inhibition of
FIG. 2. GIP treatment induces CGRP-I and CT mRNA expression and CGRP protein release in
human adipocytes. A, Differentiated human preadipocyte-derived adipocytes were treated
with the indicated concentrations of GIP for 1 h. B, Differentiated human preadipocyte-
derived adipocytes were treated with 1 nM GIP for the indicated period of time. mRNA
expression was assessed by real-time PCR. mRNA level are shown as fold of control
normalized to HPRT expression levels. Results are expressed in arbitrary units with the control
value taken as 1 and are the means  SEM of at least five independent experiments all carried
out in triplicate. *, P  0.05, **, P  0.01, ***, P  0.001 vs. control. C, Differentiated
human adipocytes were treated with 1 nM GIP for 1 h (n  3), 6 h (n  2), or 24 h (n  6).
CGRP-I protein content in the cell supernatant was measured using a human-specific RIA kit.
Results are expressed in arbitrary units with the control value taken as 1 and are the means 
SEM of indicated number (n) of experiments, carried out in duplicate. *, P  0.05 vs. control.
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PKA, the direct downstream signaling pathwaymodule of
cAMP, by H-89 (20 M) efficiently blocked the GIP me-
diated stimulation of CGRP-I (P  0.001 vs. GIP 1 nM,
1h) andCTmRNAexpression (P0.01 vs.GIP1nM,1h)
(data not shown).
Because cAMP is often acting in synergismwith [Ca2]i
signaling, we tested the effect of ionomycin, a calcium-
mobilizing agent. Treatment of differentiated adipocytes
with ionomycin (1 M, 6 h) potentiated the stimulatory
effect ofGIP onCGRP-I (P 0.001 vs.GIP 1 nM, 6 h) and
CT gene expression (P 0.01 vs.GIP 1 nM, 6 h) (data not
shown). Costimulation with GIP (1 nM) and ionomycin (1
M) for 24 h induced secretion of CGRP-I 1.6 0.1-fold
(P  0.001 vs. control) and Pro-CT 9.7  1.4-fold (P 
0.001 vs. control) (data not shown).
CGRP-I and CT mRNA levels are altered in sc and
visceral AT of obese subjects
Examiningpaired sc andvisceralAT samples,we found
increasedCGRP-ImRNAexpression in scATofmorbidly
obese patients (P  0.05 vs. lean subjects), whereas
CGRP-I gene expression in visceral AT was not signifi-
cantly altered (P 0.2 vs. lean subjects) (data not shown).
In contrast,CTmRNAexpressionwasnot altered in scAT
(P 0.6 vs. lean subjects) but was induced in visceral AT
ofmorbidly obese patients (data not shown).Moreover, a
positive correlation with BMI was found for CGRP-I
mRNA expression (n  20; r  0.54; P  0.05) and CT
mRNA expression in visceral AT (n  20; r  0.45; P 
0.05). Correlation with BMI tended to be significant for
CGRP-ImRNAexpression in scAT (n20; r0.43;P
0.06) but not for sc CT mRNA expression.
Discussion
Our results demonstrate that GIP induces CALC-I gene
expressionandprotein secretionofCGRP-I andPro-CT in
human adipocytes via GIP-R activation, involving the
cAMP/PKAmodule and [Ca2]i signaling pathways. Fur-
thermore, we found increased mRNA expression of
CGRP-I and CT in sc and visceral AT samples of obese
compared with lean control subjects. Additionally,
CGRP-I protein contentwas increased andPro-CT tended
to be increased in plasma samples of obese patients after
a high-fat meal ingestion.
In agreement with other human adipocyte models (10,
30), we found GIP-R mRNA to be barely expressed in
undifferentiatedprimaryhumanpreadipocytes. Induction
of GIP-R during differentiation was accompanied by ex-
pression of other adipocyte specific markers like leptin.
Functional analysis of GIP-R in our differentiated adipo-
cytes confirmed the results described for GIP-R in another
human adipocytemodel (10).However, and in contrast to
Weaver et al. (10), who reported a peak ofGIP-RmRNA
expression at d 6–8 and a decreased expression to 50%at
d 14 of differentiation in Simpson-Golabi-Behmel syn-
drome preadipocyte-derived adipocytes, we found near-
to-maximal GIP-R mRNA expression levels already at d
7 of differentiation with a stable expression pattern up to
d 14 of differentiation process in our human adipocytes.
This discrepancy might most likely be attributed to dif-
ferences in the primary preadipocytes used.
Treatment with GIP directly induced mRNA expres-
sion of CGRP-I and its splice variant CT in a dose-and
time-dependent manner. Regarding possible signaling
pathways transducing the GIP effect on CGRP-I and CT
expression and secretion, we found the cAMP/PKA path-
way as well as [Ca2]i to be involved. Both cAMP/PKA
and [Ca2]i mediate lipopolysaccharide (LPS)-induced
CGRP release in cultured neonatal rat dorsal root gan-
glion neurons (31). In accordance we recently demon-
strated a crucial role for [Ca2]i in LPS-induced CALC-I
gene expression and protein release of CGRP-I and
Pro-CT in human adipocytes (16). In GIP-treated human
adipocytes, only CGRP-I protein was secreted shortly af-
ter GIP treatment alone, whereas cotreatment with the
ionophor ionomycin induced significant protein secretion
of both CGRP-I and Pro-CT. This suggests that GIP-in-
duced secretion of Pro-CT by adipocytes takes place only
if cells are primed by other stimuli.
Arecentstudyprovidedstrongevidenceforanassociation
of Pro-CT plasma levels with obesity, insulin resistance, and
themetabolic syndrome (19). Some studies provided further
evidence for the detrimental effects of Pro-CT in states of
systemic inflammation and sepsis (32, 33). The secretion of
Pro-CT in the AT of obese patients might thereby further
accelerate local proinflammatory activity in AT. Further-
more, CGRP-1 has been shown to directly induce insulin
resistance (21–23, 34) and to impair glucose-induced insulin
secretion (24, 35). Therefore, CGRP-I and Pro-CT might
mediate GIP-induced insulin resistance in diet-induced obe-
sity and related metabolic dysfunctions.
As a physiological link to our in vitro findings, human
CGRP plasma levels increase after an oral fat load (20),
which is also a trigger for GIP release (1). However, an-
other study found no systemic increase of CGRP after oral
fat ingestion (36). Due to the controversy of these reports,
we measured CGRP-I and Pro-CT levels in plasma sam-
ples of 24 highly obese patients before and 180 min after
ingestion of a high-fat test meal. We found an increase in
CGRP-I plasma levels to 1.9  0.3-fold (P  0.05 vs.
fasted) and a slight increase in Pro-CT levels to 1.1 
0.1-fold (P0.07 vs. fasted; data not shown). The finding
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that the Pro-CT plasma levels were not significantly in-
creasedmight be attributed to the fact that concentrations
of this hormone were measured only at one time point
(180min) after meal ingestion. Pro-CT plasma levels after
endotoxin injection have been reported to rise at the ear-
liest within 3–6 h (37). Therefore, we might have missed
a significant increase of Pro-CT concentrations at a later
postprandial time point.
The induction of Pro-CT and CGRP by GIP in human
adipocytes might be also of clinical relevance in another
context. Glucagon-like peptide-1 (GLP-1), another incre-
tin hormone, is used for the treatment of diabetes mellitus
type 2. GLP-1 analogs have been shown to induce CT and
CGRP expression and secretion in a murine C cell line
(38). Furthermore, a long-acting GLP-1 receptor agonist,
liraglutide, is associated with increased risk of thyroid C
cell adenomas and carcinomas in rats and mice (39). Ac-
cordingly, the Food and Drug Administration requested
long-term follow-up on rates of medullary cancer in pa-
tients treated with this drug. Dipeptidyl peptidase-IV in-
hibitors increase plasma levels of GLP-1 and GIP in vivo
(40) and are widely used for the treatment of diabetes
mellitus type 2.Our findings, thatGIP is inducingCALC-I
gene expression in humanadipocytes, should further stim-
ulate research investigating the effect of GIP in human
thyroid C cells to cast light on any potential medullary
thyroid carcinoma developing in patients treated with
Dipeptidyl peptidase-IV inhibitors or newly developed
GIP agonists/analogs.
In summary, our study shows that GIP is directly in-
ducing CGRP-I and Pro-CT in human adipocytes. To-
gether with the findings that CGRP-I and CTmRNA ex-
pression levels in visceral AT were positively correlated
with BMI, these results provide strong evidence for a role
of CGRP-I and Pro-CT as markers for adipocyte dysfunc-
tion in obesity.
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